We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Solicitor General of the United States has advised the Supreme Court not to review the FTC’s antitrust case against Schering-Plough — a development that could defeat the agency’s effort to kill the practice of “reverse payments,” where drugmakers pay generic competitors to delay launching their version of the innovator’s product.
Andrx and Watson Pharmaceuticals have received a second request from the FTC for additional information in connection with Watson’s impending purchase of Andrx, the companies said May 3.
AstraZeneca announced it will buy the remaining shares of UK-based Cambridge Antibody Technology Group (CAT) for just over the equivalent of $1.07 billion.
SkyePharma has entered into an agreement with Kos Pharmaceuticals to jointly develop and market Flutiform, which the company believes could be a $1 billion-a-year new asthma treatment.
Andrx’s CEO will get a $700,000 bonus for 2005 despite manufacturing problems that have stalled all the company’s pending drug applications, according to documents filed with the Securities and Exchange Commission (SEC).
Andrx and Watson Pharmaceuticals have received a second request from the FTC for additional information in connection with Watson’s impending purchase of Andrx, the companies said May 3.
Pharma manufacturers face a mandate from seven states and the District of Columbia to make sure their IT systems can provide a record of the gifts their sales reps have made to physicians, and the other 43 states are likely to follow within 12 to 18 months, according to a new study by Gartner.
Sanofi-aventis said it would acquire all Japanese rights to the experimental antiobesity and smoking-cessation drug Acomplia from Fujisawa sanofi-aventis, a joint venture of sanofi-aventis and Japan’s Astellas Pharma.